

House Bill 3022

Sponsored by Representatives GREENLICK, TOMEI, Senator ROSENBAUM; Representatives BARNHART, BENTZ, BERGER, COWAN, D EDWARDS, ESQUIVEL, FREEMAN, GARRARD, GELSER, GILLIAM, HOLVEY, HUFFMAN, JENSON, KENNEMER, KOTEK, KRIEGER, MAURER, NATHANSON, OLSON, SCHAUFLEER, SHIELDS, THOMPSON, Senators BONAMICI, DINGFELDER, MONNES ANDERSON, MORRISETTE, TELFER, VERGER

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**.

Authorizes practitioner to prescribe antibiotic drug to patient for use by patient and each sexual partner of patient to treat gonorrhea and chlamydia.

A BILL FOR AN ACT

1
2 Relating to treatment of sexually transmitted diseases; creating new provisions; and amending ORS
3 689.505.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1. Section 2 of this 2009 Act is added to and made a part of ORS 475.005 to**
6 **475.285.**

7 **SECTION 2. (1) As used in this section:**

8 (a) **"Partner of a patient" means a person whom:**

9 (A) **A practitioner does not directly diagnose; and**

10 (B) **A patient identifies as a sexual partner of the patient.**

11 (b) **"Sexually transmitted disease" means gonorrhea or chlamydia.**

12 (2) **When a practitioner diagnoses a patient with a sexually transmitted disease, the**
13 **practitioner may prescribe an antibiotic drug to the patient for use by the patient and each**
14 **partner of the patient.**

15 (3) **A prescription dispensed to a patient for use by the patient and each partner of the**
16 **patient must include the name of the patient, the number of doses to be dispensed to the**
17 **patient, the name of each partner of the patient and the number of doses to be dispensed to**
18 **each partner of the patient.**

19 (4) **When a practitioner prescribes an antibiotic drug to a patient for use by the patient**
20 **and each partner of the patient, the practitioner shall distribute informational material**
21 **about the sexually transmitted disease to the patient.**

22 (5) **The Department of Human Services shall provide practitioners with the informational**
23 **material to be distributed pursuant to subsection (4) of this section.**

24 **SECTION 3. ORS 689.505 is amended to read:**

25 689.505. (1)(a) Except as specifically provided by law, no person shall distribute or dispense any
26 drug without affixing to the authorized container a clear and legible label, either printed or written,
27 bearing the name of the drug and the name and place of business of the person distributing or dis-
28 pensing the drug, and any other information required by state law or rules or federal law or regu-
29 lations under whose supervision the drug is delivered or dispensed.

NOTE: Matter in **boldfaced** type in an amended section is new; matter [*italic and bracketed*] is existing law to be omitted. New sections are in **boldfaced** type.

1 (b) Labeling requirements regarding any drug may be changed or exemption therefrom granted
2 by the State Board of Pharmacy in the form of a special permit if the board determines that a
3 change or exemption is in the best interest of public health and safety.

4 (2)(a) No manufacturer or wholesaler subject to ORS 689.305 shall sell or otherwise distribute,
5 or offer to sell or otherwise distribute, any drug for use in a:

6 (A) Parcel, package or container not bearing a label specifying the name, active ingredients or
7 contents, quality and quantity of the drug.

8 (B) Misbranded parcel, package or container.

9 (b) A parcel, package or container is misbranded:

10 (A) If its labeling is false or misleading in any particular.

11 (B) Unless it bears a label containing the name and business address of the manufacturer,
12 packer, distributor or wholesaler, and an accurate statement of the quantity of the drug in terms
13 of weight, measure or numerical count, exclusive of wrappers, cartons, containers or other materials
14 packed with such drug.

15 (C) In case it contains controlled substances which the board finds and by rule designates after
16 reasonable notice and opportunity for hearing to be habit forming, unless it bears the statement
17 "Warning--May Be Habit Forming."

18 (D) Unless it bears a label with adequate directions for the safe use of the drug for specified
19 conditions, and adequate warning against use in those pathological conditions or by children where
20 such use may be dangerous to the health or welfare of a user.

21 (E) Unless it bears a label with true representations of the intended uses of the drug and no
22 false claims or representations are made of the drug in accompanying literature or advertising.

23 (3) This section does not apply to parcels, packages or containers containing:

24 (a) Drugs prepared and packaged solely for use by a pharmacist in compounding prescriptions
25 or for dispensing in dosage unit form upon a prescription, except that such parcels, packages or
26 containers must bear the name and business address of the manufacturer and, if different, the name
27 and business address of the distributor of the drug, and the legend "Caution: Federal Law Prohibits
28 Dispensing Without Prescription" or an equivalent legend.

29 (b) Drugs intended solely for use in the professional diagnosis of disease, except that such par-
30 cels, packages or containers shall bear the statement "Diagnostic Reagent--For Professional Use
31 Only."

32 (c) Coloring agents, emulsifiers, excipients, flavorings, lubricants, preservatives and other like
33 inactive ingredients used in the manufacture of drugs.

34 (4) The board shall by rule exempt from any labeling or packaging requirement of this section
35 drugs which are, in accordance with the practice of the trade, to be processed, labeled or repacked
36 in substantial quantities at establishments other than those where originally processed or packed.
37 However, such drugs must not be adulterated or misbranded upon removal from such processing,
38 labeling or repacking establishment.

39 (5) A pharmacist or pharmacy intern shall not dispense, on the prescription of a practitioner,
40 any drug without affixing to the container thereof a clear and legible label. The label may be printed
41 or written. Except as provided in subsection (6) of this section, the pharmacist or pharmacy intern
42 shall state or cause to be stated on the label the following:

43 (a) The name of the drug. If the dispensed drug does not have a brand name, the prescription
44 label shall indicate the generic name of the drug dispensed along with the name of the drug dis-
45 tributor or manufacturer, its quantity per unit and the directions for its use stated in the pre-

1 scription. However, if the drug is a compound, the quantity per unit need not be stated[;].

2 (b) The name of the practitioner prescribing the drug[;].

3 (c) The name and place of business of the pharmacist or the name and place of business of the
4 pharmacy for which the pharmacist or pharmacy intern is acting[;].

5 (d) The name of the patient[; *and*].

6 **(e) If the practitioner prescribes an antibiotic drug to a patient pursuant to section 2 of**
7 **this 2009 Act, the number of doses to be dispensed to the patient, the name of each partner**
8 **of the patient as defined in section 2 of this 2009 Act and the number of doses to be dispensed**
9 **to each partner of the patient.**

10 [(e)] (f) When applicable and as determined by the State Board of Pharmacy, an expiration date
11 after which the patient should not use the drug.

12 (6) If the prescribing practitioner so directs, the prescription label shall not state the name and
13 quantity per unit of the drug.

14 (7) The State Board of Pharmacy shall determine those drugs which must bear an expiration
15 date under subsection (5)(e) of this section.

16 (8) As used in this section, “compound” means a drug containing two or more medically active
17 ingredients.

18 (9) No person shall deliver or dispense any drug for use by the ultimate consumer without la-
19 beling the drug container as required in this section.

20 (10) In addition to the labeling requirements imposed by subsections (1) to (9) of this section, the
21 board may impose by rule requirements for drug code imprints on solid dose legend drugs.

22